# respiratory system infections

Data Table



| Disease name | Causative organisms | Agent/vector | Agent factors | Source of infection | Infectivity | Secondary attack rate | Vector control measures | Age of host | Type of immunity | Special Effects during pregnancy if any | Environmental factors | Transmission | Incubation period | Clinical features | Complications | Diagnosis(all methods) | Prevention |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Smallpox | Variola virus | Not in source | Poxviridae family; stable virus; absence of animal reservoir, human carriers, or subclinical cases. | Case of smallpox (variola major, minor, or sine eruption). | Highly infectious; communicable from 2-3 days before rash until all scabs fall off. | 30-45% | Not applicable | All ages; infants and elderly have higher fatality. | Solid long-term immunity after attack; durable immunity after vaccination. | High maternal mortality; risk of abortion. | Cooler seasons; spread by direct airborne currents. | Direct droplet spread, droplet nuclei, or indirect contact with contaminated dust/fomites. | 7-17 days (average 12 days) | Sudden onset; severe prodrome (fever, headache, backache); centrifugal maculopapular to pustular rash (palms/soles affected). | Disfiguration, blindness, limb deformities, death. | Clinical presentation; tissue culture; electron microscopy; PCR; serology. | Eradicated; historically via Smallpox vaccine (bifurcated needles); surveillance and containment. |
| Chicken pox | Varicella-zoster virus (VZV) / Human herpes virus 3 | Not in source | DNA virus; establishes latent infection in sensory ganglia; fragile (dies within 2 days off host); heat labile. | Cases of chickenpox or herpes zoster (shingles); oropharyngeal secretions and lesion fluid. | Highly infectious; communicable 1-2 days before rash to 4-5 days after (until scabs form). | 85-90% | Not applicable | Primarily children <10 years; can be severe in adults. | Durable immunity; IgG persists for life; maternal antibody protects for first few months. | Congenital varicella syndrome (0.4-2.0% risk in first 20 weeks); risk of foetal wastage. | Winter and spring seasons; high humidity; overcrowding. | Droplet infection, droplet nuclei (aerosol), direct contact with lesions, or vertical (transplacental). | 14-16 days (range 10-21 days) | Fever, malaise; Pleomorphic centripetal rash (macule to "dew-drop" vesicle); affects axilla; spares palms/soles. | Secondary bacterial infections (Staph/Strep), pneumonia, encephalitis, Reye's syndrome, cerebellar ataxia. | Clinical signs; PCR (DNA detection); Tzanck smear; Direct immunofluorescence (DFA); Serology (IgM/IgG). | Isolation (6 days after rash); Live attenuated vaccine (OKA strain); Varicella-zoster immunoglobulin (VZIG). |
| Measles | Measles virus (RNA paramyxovirus) | Not in source | Morbillivirus; one serotype; survives at sub-zero temp; killed by heat/sunlight; short survival outside host. | Case of measles; respiratory secretions; no known carriers. | Highly infectious during prodromal stage (4 days before to 5 days after rash). | 80-90% | Not applicable | Children 6 months to 3 years in endemic areas; rare in infants <5 months. | Lifelong immunity after infection; solid immunity after vaccination. | Risk of spontaneous abortion, premature delivery; no known congenital abnormalities. | Winter and early spring; high population density; overcrowding. | Droplet infection, droplet nuclei (aerosols), conjunctiva, or vertical (fetal). | 10-14 days (average 10 days to fever, 14 to rash) | Fever, coryza, cough, conjunctivitis; Koplik's spots (pathognomonic); Dusky-red maculopapular rash (retro-auricular). | Pneumonia (most common death), otitis media, diarrhea, SSPE, blindness (Vitamin A deficiency). | Clinical (Koplik's spots); IgM ELISA serology; RT-PCR (throat swab/urine); Virus isolation. | Live attenuated vaccine (Edmonston-Zagreb strain); Vitamin A supplementation; Measles Immunoglobulin (post-exposure). |
| Rubella | Rubella virus (RNA Togavirus) | Not in source | One antigenic type; teratogenic potential; photo-degradable; heat sensitive. | Clinical or subclinical cases; infants with CRS (shed virus for months). | Highly contagious; communicable 1 week before to 1 week after rash. | Not in source | Not applicable | Children and young adults (3-10 years in developing countries). | Solid long-term immunity; maternal protection for 4-6 months. | Congenital Rubella Syndrome (CRS): 90% risk in 1st trimester; MTP advised if infected early. | Overcrowding; winter and spring climate/epidemics. | Droplet infection; direct contact; transplacental (vertical) to fetus. | 14-21 days (average 18 days) | Low-grade fever, lymphadenopathy (post-auricular), 3-day maculopapular rash (starts on face). | CRS (cataracts, deafness, heart defects), arthritis (adults), encephalitis (rare). | Clinical; Serology (IgM, 4-fold IgG rise); RT-PCR; Heme-agglutination Inhibition (HI) test. | Live attenuated vaccine (RA 27/3 strain) as monovalent, MR, or MMR; screening childbearing women. |
| Mumps | Mumps virus (RNA Myxovirus) | Not in source | Genus Rubulavirus; one serotype; predilection for glandular and nervous tissues. | Clinical and subclinical cases; saliva. | Highly infectious 4-7 days before parotitis to 7 days after. | Approximately 86% | Not applicable | Most frequent in children 5-15 years; rare in infants. | Lifelong immunity; maternal immunity for first 6 months. | Possible abortion in first trimester; no known congenital malformations. | Winter and spring; associated with overcrowding. | Droplet infection; direct contact; fomites. | 14-21 days (average 18 days) | Fever, parotid gland swelling/tenderness (obliterates sulcus), pain on swallowing; Cowie's sign. | Orchitis (post-pubertal), oophoritis, meningitis, pancreatitis, sensorineural deafness, B-cell destruction. | Clinical; IgM ELISA; Virus isolation (saliva, CSF, blood); Rise in IgG. | Live attenuated vaccine (Jeryl-Lynn or L-Zagreb strains); MMR vaccine; isolation. |
| Influenza | Influenza virus (Types A, B, C) | Ducks, chickens, pigs (Type A) | Antigenic drift (minor) and shift (major); RNA Orthomyxoviridae; H and N surface antigens. | Case or subclinical case; animal reservoirs (birds, pigs, horses). | Highly contagious; communicable 1-2 days before to 5-7 days after symptoms. | Variable; high in closed communities (20-30% in children). | Not applicable | All ages; high-risk in elderly (>65) and young children. | Strain-specific; short-lived (6-12 months); no cross-immunity between types. | Pregnancy is a risk factor for severe disease/complications. | Winter peaks; rainy season in tropics; overcrowding; poor ventilation. | Droplet infection, droplet nuclei (aerosols), or direct/indirect contact. | 1-5 days (average 2 days) | Sudden fever, chills, malaise, myalgia, cough, sore throat, congested conjunctivae. | Pneumonia (secondary bacterial or viral), bronchitis, Reye syndrome (if aspirin used in children), Guillain-Barr√©. | RT-PCR (nasopharyngeal swab); Viral culture; Rapid Diagnostic Tests (RDTs); Serology. | Inactivated (IIV) or Live attenuated (LAIV) vaccine; Oseltamivir/Zanamivir; Hand hygiene; Respiratory etiquette. |
| Diptheria | Corynebacterium diphtheriae | Not in source | Gram-positive bacillus; produces exotoxin (Fragment A and B); sensitive to heat/sunlight; stands cold. | Patients, mild cases, and carriers (nasal/throat/skin). | Communicable for 2-4 weeks (terminated by chemotherapy). | ~10% in some contexts | Not applicable | Children 1-5 years; shifting to older ages in vaccinated areas. | Acquired via infection or toxoid; tested by Schick test; maternal IgG (6 months). | Rare. | Winter; overcrowding; lack of personal hygiene. | Direct droplet; contact with skin lesions; fomites; contaminated milk. | 2-6 days (average 3-4 days) | Sore throat, low fever; Adherent greyish-white pseudomembrane; 'Bull-neck' appearance. | Myocarditis, polyneuritis (nerve paralysis), respiratory obstruction/failure. | Clinical (membrane); Swab culture (Loeffler's serum); Toxin production test (Elek's); PCR. | DPT or Pentavalent vaccine; DT/Td boosters; Diphtheria antitoxin (ADS); Chemoprophylaxis (Erythromycin). |
| Whooping cough | Bordetella pertussis | Not in source | Gram-negative coccobacillus; produces exotoxin/endotoxin; dies quickly outside host. | Infected humans (cases); no subclinical or chronic carrier state. | Highest in catarrhal stage; ends 3 weeks after paroxysms begin. | 80-90% | Not applicable | Infants and children <5 years; no passive inherited immunity. | Prolonged immunity via infection or vaccine (6-12 years). | None specific. | Winter season; temperate climate; overcrowding. | Droplet infection; direct contact; fomites. | 7-14 days (max 21 days) | Catarrhal stage (insidious cough); Paroxysmal stage (bouts of cough with inspiratory 'whoop'); vomiting. | Bronchitis, bronchopneumonia, hernia, subconjunctival hemorrhage, encephalopathy. | Nasopharyngeal swab culture (Bordet-Gengou); PCR; Direct fluorescent antibody (DFA); Serology. | DPT (whole cell or acellular) or Pentavalent vaccine; Erythromycin/Azithromycin for contacts. |
| Meningococcal meningitis | Neisseria meningitidis | Not in source | Gram-negative diplococci; Serotypes A, B, C, W135, Y; produces endotoxin. | Nasopharynx of cases and carriers (asymptomatic carriers are crucial). | Communicable until 24 hours after starting effective therapy. | High in household contacts; most within 72h of index case. | Not applicable | Children and young adults; peak in infants 3-12 months. | Group-specific immunity via infection or vaccination. | Vaccines safe during pregnancy; some sources suggest contraindication for specific strains. | Dry/cold months; overcrowding (schools, barracks, jails). | Droplet infection via nasopharyngeal route. | 3-4 days (range 2-10 days) | Sudden onset headache, fever, nausea, vomiting, neck rigidity (Kernig's/Brudzinski's sign), petechial rash. | Septicemia, shock (Waterhouse-Friderichsen), deafness, permanent neurological damage. | Lumbar puncture (purulent CSF); Gram staining; CSF/Blood culture; Latex agglutination; PCR. | Polysaccharide or Conjugate vaccine; Chemoprophylaxis (Rifampicin/Ciprofloxacin) for contacts. |
| Acute respiratory infections | Viruses (RSV, Influenza) and Bacteria (S. pneumoniae, H. influenzae) | Not in source | Multiple pathogens; some vaccine preventable; antimicrobial resistance. | Infected cases and carriers. | Highly infectious through respiratory particles. | Higher in siblings of school-going children. | Not applicable | Children <5 years at highest risk; elderly. | Transient/specific to pathogen; acquired via vaccines (PCV, Hib). | High risk of severity if infected. | Cold weather; indoor air pollution (biomass fuel); overcrowding; low birth weight. | Droplet infection; direct contact with secretions; airborne. | Variable (usually 1-5 days) | Cough, runny nose, fever, breathing difficulty (tachypnea), chest indrawing, stridor, wheezing. | Pneumonia, heart failure, septicemia, meningitis, respiratory failure. | Clinical signs (WHO IMNCI criteria); Respiratory rate count; Chest X-ray; Sputum culture; Pulse oximetry. | Vaccination (Measles, Hib, PCV, DPT); breastfeeding; reducing smoke; proper case management (IMCI). |
| Severe acute respiratory syndrome | SARS coronavirus (SARS-CoV) | Horseshoe bat (reservoir); Civets (amplifier) | Survives hours on surfaces, days in waste; sensitive to heat. | Severely ill patients (max shedding on day 10). | Efficient transmission in 2nd week of illness; moderate communicability. | ~10% | Not applicable | Adults primarily; children rarely affected; high mortality in >65 years. | Widespread susceptibility; immunity not fully understood. | High risk of miscarriage and maternal death. | Hospital settings (aerosol-generating procedures); travel hubs. | Direct/indirect contact with droplets; aerosols; fomites; respiratory route. | 2-7 days (commonly 3-5 days) | Fever, malaise, chills, headache, myalgia; rapid deterioration to hypoxia and dry cough. | ARDS, pulmonary decompensation, nosocomial infections, respiratory failure. | RT-PCR (nasopharyngeal/stool); ELISA; Chest X-ray (patchy shadowing); Virus isolation. | No vaccine; isolation; PPE; hospital infection control; exit screening for travelers. |
| COVID-19 | SARS-CoV-2 | Speculated animal origin (Betacoronavirus) | ssRNA virus; petal spikes; mutates (Alpha, Delta, Omicron); sensitive to UV/solvents. | Infected people (symptomatic/asymptomatic). | Highly infectious; communicable 1-3 days before symptoms up to 3 weeks. | Variable; estimated 9-13 cases per household contact. | Not applicable | All ages; risk increases with age (>60) and comorbidities. | Vaccine-induced (Active) or infection-acquired. | Risk of severe disease/preterm birth; vaccination recommended for pregnant/lactating women. | Indoor settings with poor ventilation; crowded settings. | Respiratory droplets, aerosols, direct contact, fomites. | 2-14 days (average 5-6 days) | Fever, cough, fatigue, loss of smell/taste (anosmia/ageusia), dyspnoea. | ARDS, sepsis, multiorgan failure, Mucormycosis (Black Fungus), Post-COVID conditions. | NAAT (RT-PCR); Rapid Antigen Test (RAT); Chest CT; HRCT; Serology (IgG/IgM). | Vaccination (Covishield, Covaxin, etc.); Masking; Physical distancing; Hand hygiene; Quarantine. |
| tuberculosis | Mycobacterium tuberculosis (human); M. bovis (bovine) | Not in source | Acid-fast bacillus; facultative intracellular parasite; drug resistance (MDR/XDR/TDR); sensitive to heat/UV. | Human case (sputum positive); infected milk (Bovine). | 1 infectious case can infect 10-15 people per year; treatment reduces infectivity by 90% in 48h. | Not in source | Not applicable | All ages; peak 15-45 years; high risk in infants. | Cell-mediated immunity (T-cells); tested by Tuberculin (Mantoux) test. | Maternal/perinatal morbidity; risk of congenital TB; some drugs (Streptomycin) contraindicated. | Poverty; overcrowding; poor housing/ventilation; indoor air pollution; tobacco smoke. | Inhalation (droplet nuclei); ingestion (milk); surface implantation. | 3-6 weeks (infection to TST+); disease may take months/years. | Persistent cough (>2 weeks), evening pyrexia, night sweats, weight loss, hemoptysis, chest pain. | Intestinal perforation, skeletal TB, meningitis, miliary TB, pulmonary insufficiency. | Sputum Smear (ZN/LED-FM); Culture (LJ/MGIT); NAAT (CBNAAT/Truenat); LPA; Chest X-ray; Mantoux test. | BCG vaccination; DOTS; SCC chemotherapy (daily FDCs); TB preventive treatment (IPT); Cough etiquette. |